246 related articles for article (PubMed ID: 86042)
1. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
Frijlink WB; Bijvoet OL; te Velde J; Heynen G
Lancet; 1979 Apr; 1(8120):799-803. PubMed ID: 86042
[TBL] [Abstract][Full Text] [Related]
2. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.
Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Edouard C; Vignon C; Mathieu L; Trechsel U
Lancet; 1979 Sep; 2(8141):489-92. PubMed ID: 90215
[TBL] [Abstract][Full Text] [Related]
3. Human calcitonin in the treatment of Paget's bone disease.
Woodhouse NJ; Bordier P; Fisher M; Joplin GF; Reiner M; Kalu DN; Foster GV; MacIntyre I
Lancet; 1971 Jun; 1(7710):1139-43. PubMed ID: 4102856
[No Abstract] [Full Text] [Related]
4. [Treatment of Paget's disease with salmon calcitonin].
Manderlier T; Fuss M; Brauman J; Orloff S; Bergans A; Corvilain J
Rev Rhum Mal Osteoartic; 1977 Jan; 44(1):59-66. PubMed ID: 319520
[No Abstract] [Full Text] [Related]
5. Diphosphonates in Paget's disease.
Russell RG; Smith R; Preston C; Walton RJ; Woods CG
Lancet; 1974 May; 1(7863):894-8. PubMed ID: 4133419
[No Abstract] [Full Text] [Related]
6. Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget's disease of bone.
Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Vignon E; Trechsel U; Mathieu L; Edouard C
Adv Exp Med Biol; 1980; 128():299-309. PubMed ID: 6448538
[No Abstract] [Full Text] [Related]
7. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
[TBL] [Abstract][Full Text] [Related]
8. Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone.
Heynen G; Delwaide P; Bijvoet OL; Franchimont P
Eur J Clin Invest; 1982 Feb; 12(1):29-35. PubMed ID: 6802650
[No Abstract] [Full Text] [Related]
9. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.
Douglas DL; Duckworth T; Kanis JA; Preston C; Beard DJ; Smith TW; Underwood I; Woodhead JS; Russell RG
Arthritis Rheum; 1980 Oct; 23(10):1185-92. PubMed ID: 6448604
[TBL] [Abstract][Full Text] [Related]
11. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone.
Adami S; Zamberlan N; Mian M; Dorizzi R; Rossini M; Braga B; Gatti D; Bertoldo F; Locascio V
Bone Miner; 1994 May; 25(2):75-82. PubMed ID: 8086853
[TBL] [Abstract][Full Text] [Related]
12. Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate).
Fraser TR; Ibbertson HK; Holdaway IM; Rutland M; King A; Dodd G; Wattie DJ
Aust N Z J Med; 1984 Dec; 14(6):811-8. PubMed ID: 6442563
[TBL] [Abstract][Full Text] [Related]
13. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone.
Delmas PD; Chapuy MC; Vignon E; Charhon S; Briancon D; Alexandre C; Edouard C; Meunier PJ
J Clin Endocrinol Metab; 1982 Apr; 54(4):837-44. PubMed ID: 6460781
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP).
Rashid M; Khairi A; Johnston C
Clin Orthop Relat Res; 1977; (127):94-105. PubMed ID: 410576
[No Abstract] [Full Text] [Related]
15. Treatment of Paget's disease of bone with porcine calcitonin.
Eisman JA; Xipell JM; Sloman JG; Jerums G; Martin TJ
Med J Aust; 1974 Apr; 1(15):564-8. PubMed ID: 4858264
[No Abstract] [Full Text] [Related]
16. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.
Thiébaud D; Jaeger P; Gobelet C; Jacquet AF; Burckhardt P
Am J Med; 1988 Aug; 85(2):207-12. PubMed ID: 3261129
[TBL] [Abstract][Full Text] [Related]
17. Histological measurements in Paget's disease of bone.
Walton RJ; Woods CG; Russell RG; Kanis JA; Clark MB
Calcif Tissue Res; 1977 May; 22 Suppl():295-7. PubMed ID: 912533
[No Abstract] [Full Text] [Related]
18. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient.
Drake S; Massie JD; Postlethwaite AE; Palmieri GM
Arch Intern Med; 1989 Feb; 149(2):401-3. PubMed ID: 2783843
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of Paget's disease of bone with ethane-1 hydroxy-1, 1 diphosphonate at low dosage (author's transl)].
Alexandre C; Chapuy MC; Bressot C; Vignon E; Arlot M; Mathieu L; Edouard C; Johnston CC; Meunier PJ
Nouv Presse Med; 1980 Nov; 9(45):3429-33. PubMed ID: 6777752
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers of bone turnover in Paget's disease.
Russell RG; Beard DJ; Cameron EC; Douglas DL; Forrest AR; Guilland-Cumming D; Paterson AD; Poser J; Preston CJ; Milford-Ward A; Woodhead S; Kanis JA
Metab Bone Dis Relat Res; 1981; 3(4-5):255-62. PubMed ID: 6220191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
